

Personalised Cancer Medicine Flashcards 2025

Prostate Cancer



Standard

BRCA1 and BRCA2*

*germ-line and somatic

Recommended

CHECK2, PALB2, CDK12,
RAD51D, ATM, FANCA*

Microsatellite instability (MSI-H,
dMMR)**

*germ-line and somatic

** By either IHC (MLH1, PMS2, MSH2 a MSH6) or by genomic
study(BAT25 and BAT26, D2S123, D5S346 and D17S250).

Currently not recommended

Androgen receptor aberrations
PDL1
PTEN

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System

The **Recommended** category is based on current recommendations by EMEA and FDA

1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440.
2. To SQ, Kwan EM, Fettke HC, et al. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018 Jun;73(6):818-821. doi: 10.1016/j.eururo.2018.01.007.
3. González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clin Transl Oncol. 2021 May;23(5):969-979. doi: 10.1007/s12094-021-02561-5.
4. Fenton SE, VanderWeeler DJ, Rebbeck TR, Chen DL. Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433138. doi: [10.1200/EDBK_433138](https://doi.org/10.1200/EDBK_433138)



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

